|
1
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bazarbachi A, Ghez D, Lepelletier Y, Nasr
R, de Thé H, El-Sabban ME and Hermine O: New therapeutic approaches
for adult T-cell leukaemia. Lancet Oncol. 5:664–672. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marks DI and Rowntree C: Management of
adults with T-cell lymphoblastic leukemia. Blood. 129:1134–1142.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johnson DE: The ubiquitin-proteasome
system: Opportunities for therapeutic intervention in solid tumors.
Endocr Relat Cancer. 22:T1–T17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kouroukis TC, Baldassarre FG, Haynes AE,
Imrie K, Reece DE and Cheung MC: Bortezomib in multiple myeloma:
Systematic review and clinical considerations. Curr Oncol.
21:e573–e603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Orlowski RZ and Kuhn DJ: Proteasome
inhibitors in cancer therapy: Lessons from the first decade. Clin
Cancer Res. 14:1649–1657. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Horton TM, Pati D, Plon SE, Thompson PA,
Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M
and Blaney SM: A phase 1 study of the proteasome inhibitor
bortezomib in pediatric patients with refractory leukemia: A
children's oncology group study. Clin Cancer Res. 13:1516–1522.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bertaina A, Vinti L, Strocchio L, Gaspari
S, Caruso R, Algeri M, Coletti V, Gurnari C, Romano M, Cefalo MG,
et al: The combination of bortezomib with chemotherapy to treat
relapsed/refractory acute lymphoblastic leukaemia of childhood. Br
J Haematol. 176:629–636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Howard DS, Liesveld J, Phillips GL II,
Hayslip J, Weiss H, Jordan CT and Guzman ML: A phase I study using
bortezomib with weekly idarubicin for treatment of elderly patients
with acute myeloid leukemia. Leuk Res. 37:1502–1508. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Messinger YH, Gaynon PS, Sposto R, van der
Giessen J, Eckroth E, Malvar J and Bostrom BC: Therapeutic Advances
in Childhood Leukemia & Lymphoma (TACL) Consortium: Bortezomib
with chemotherapy is highly active in advanced B-precursor acute
lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia
& Lymphoma (TACL) study. Blood. 120:285–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Löwenberg B, Ossenkoppele GJ, van Putten
W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J,
Jongen-Lavrencic M, von Lilienfeld-Toal M, et al: High-dose
daunorubicin in older patients with acute myeloid leukemia. N Engl
J Med. 361:1235–1248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pommier Y, Leo E, Zhang H and Marchand C:
DNA topoisomerases and their poisoning by anticancer and
antibacterial drugs. Chem Biol. 17:421–433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Crawford LJ and Irvine AE: Targeting the
ubiquitin proteasome system in haematological malignancies. Blood
Rev. 27:297–304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soligo D, Servida F, Delia D, Fontanella
E, Lamorte G, Caneva L, Fumiatti R and Lambertenghi Deliliers G:
The apoptogenic response of human myeloid leukaemia cell lines and
of normal and malignant haematopoietic progenitor cells to the
proteasome inhibitor PSI. Br J Haematol. 113:126–135. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Du XL and Chen Q: Recent advancements of
bortezomib in acute lymphocytic leukemia treatment. Acta Haematol.
129:207–214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dai Y, Chen S, Wang L, Pei XY, Kramer LB,
Dent P and Grant S: Bortezomib interacts synergistically with
belinostat in human acute myeloid leukaemia and acute lymphoblastic
leukaemia cells in association with perturbations in NF-κB and Bim.
Br J Haematol. 153:222–235. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lieu C, Chow L, Pierson AS, Eckhardt SG,
O'Bryant CL, Morrow M, Tran ZV, Wright JJ and Gore L: A phase I
study of bortezomib, etoposide and carboplatin in patients with
advanced solid tumors refractory to standard therapy. Invest New
Drugs. 27:53–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Walker AR, Klisovic RB, Garzon R, Schaaf
LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G and Blum
W: Phase I study of azacitidine and bortezomib in adults with
relapsed or refractory acute myeloid leukemia. Leuk Lymphoma.
55:1304–1308. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schelman WR, Traynor AM, Holen KD, Kolesar
JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R,
et al: A phase I study of vorinostat in combination with bortezomib
in patients with advanced malignancies. Invest New Drugs.
31:1539–1546. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Messinger Y, Gaynon P, Raetz E, Hutchinson
R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E
and Bostrom BC: Phase I study of bortezomib combined with
chemotherapy in children with relapsed childhood acute
lymphoblastic leukemia (ALL): A report from the therapeutic
advances in childhood leukemia (TACL) consortium. Pediatr Blood
Cancer. 55:254–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y,
Feng TT, Meng FY, Liu XL, Jiang QL, et al: Synergy between
proteasome inhibitors and imatinib mesylate in chronic myeloid
leukemia. PLoS One. 4:e62572009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang QL, Wang L, Zhang YW, Jiang XX, Yang
F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ and Zhao WL: The
proteasome inhibitor bortezomib interacts synergistically with the
histone deacetylase inhibitor suberoylanilide hydroxamic acid to
induce T-leukemia/lymphoma cells apoptosis. Leukemia. 23:1507–1514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hui KF, Leung YY, Yeung PL, Middeldorp JM
and Chiang AK: Combination of SAHA and bortezomib up-regulates
CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr
virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid
cell lines. Br J Haematol. 167:639–650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schimmel KJ, Richel DJ, van den Brink RB
and Guchelaar HJ: Cardiotoxicity of cytotoxic drugs. Cancer Treat
Rev. 30:181–191. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koyama D, Kikuchi J, Hiraoka N, Wada T,
Kurosawa H, Chiba S and Furukawa Y: Proteasome inhibitors exert
cytotoxicity and increase chemosensitivity via transcriptional
repression of Notch1 in T-cell acute lymphoblastic leukemia.
Leukemia. 28:1216–1226. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Song IS, Kim HK, Lee SR, Jeong SH, Kim N,
Ko KS, Rhee BD and Han J: Mitochondrial modulation decreases the
bortezomib-resistance in multiple myeloma cells. Int J Cancer.
133:1357–1367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Berges C, Haberstock H, Fuchs D, Sadeghi
M, Opelz G, Daniel V and Naujokat C: Proteasome inhibition
activates the mitochondrial pathway of apoptosis in human
CD4+ T cells. J Cell Biochem. 108:935–946. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grandjenette C, Schnekenburger M, Karius
T, Ghelfi J, Gaigneaux A, Henry E, Dicato M and Diederich M:
5-aza-2′-deoxycytidine-mediated c-myc down-regulation triggers
telomere-dependent senescence by regulating human telomerase
reverse transcriptase in chronic myeloid leukemia. Neoplasia.
16:511–528. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Voortman J, Checinska A, Giaccone G,
Rodriguez JA and Kruyt FA: Bortezomib, but not cisplatin, induces
mitochondria-dependent apoptosis accompanied by up-regulation of
noxa in the non-small cell lung cancer cell line NCI-H460. Mol
Cancer Ther. 6:1046–1053. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kroemer G, Galluzzi L and Brenner C:
Mitochondrial membrane permeabilization in cell death. Physiol Rev.
87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akiyama T, Dass CR and Choong PF:
Bim-targeted cancer therapy: A link between drug action and
underlying molecular changes. Mol Cancer Ther. 8:3173–3180. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wirth M, Stojanovic N, Christian J, Paul
MC, Stauber RH, Schmid RM, Häcker G, Krämer OH, Saur D and
Schneider G: MYC and EGR1 synergize to trigger tumor cell death by
controlling NOXA and BIM transcription upon treatment with the
proteasome inhibitor bortezomib. Nucleic Acids Res. 42:10433–10447.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen S, Zhang Y, Zhou L, Leng Y, Lin H,
Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y and Grant S: A
Bim-targeting strategy overcomes adaptive bortezomib resistance in
multiple myeloma through a novel link between autophagy and
apoptosis. Blood. 124:2687–2697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pigneux A, Mahon FX, Moreau-Gaudry F,
Uhalde M, de Verneuil H, Lacombe F, Reiffers J, Milpied N, Praloran
V and Belloc F: Proteasome inhibition specifically sensitizes
leukemic cells to anthracyclin-induced apoptosis through the
accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biol
Ther. 6:603–611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Premkumar DR, Jane EP, DiDomenico JD,
Vukmer NA, Agostino NR and Pollack IF: ABT-737 synergizes with
bortezomib to induce apoptosis, mediated by Bid cleavage, Bax
activation, and mitochondrial dysfunction in an Akt-dependent
context in malignant human glioma cell lines. J Pharmacol Exp Ther.
341:859–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Unterkircher T, Cristofanon S, Vellanki
SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM and
Fulda S: Bortezomib primes glioblastoma, including glioblastoma
stem cells, for TRAIL by increasing tBid stability and
mitochondrial apoptosis. Clin Cancer Res. 17:4019–4030. 2011.
View Article : Google Scholar : PubMed/NCBI
|
